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Abstract  
The World Health Organization and the Center for Disease Control reports Chagas disease, or 
American trypanosomiasis, as a major neglected tropical disease prevalent in 21 endemic Latin 
American countries.  The agent of the disease is a single-celled protozoan parasite, Trypanosoma 
cruzi, and common modes of transmission include infected feces of a triatomine bug, crossing 
the placental barrier, and blood products.  The two phases of infection are acute and chronic, and 
the three most affected body systems are cardiovascular, digestive, and nervous.  Although 
research has led to several advances in the knowledge of CD, there are gaps in treatment and 
epidemiological research, leaving millions of people susceptible to infection.  
Keywords: Chagas disease, Latin America, acute and chronic phases, kissing bugs, 
combination treatments  
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Introduction 
Since the original identification and description of Chagas Disease (CD) by Carlos 
Chagas in 1909, scientists have achieved substantial progress in understanding this 
anthropozoonosis (disease transmitted from animals to humans) as evidenced in the 21 endemic 
countries by the decrease in number of deaths per year from more than 45,000 in 1985 to 12,000 
in 2010 to 7,000 in 2016 (Pérez-Molina et al., 2018).  However, even with a broader knowledge 
of CD, there are nearly 6 to 8 million infected individuals worldwide and between 60 and 80 
million susceptible people living in endemic regions.  Along with the advances in the last 
century, new problems and gaps in research are becoming evident, especially during the previous 
few decades.  For example, kissing bugs (Order: Hemiptera, Family: Reduviidae, Subfamily: 
Triatominae) are the primary form of transmission and, since vector control protocols have been 
devised, other methods of spreading CD are taking the lead such as congenital transmission, 
usage of blood products, and food contamination.  Additionally, advocacy campaigns identify 
and communicate the socioeconomic implications of CD yet clinical resources such as diagnostic 
tests and treatment are still deficient within many Spanish endemic populations.  
Physiologically, there are two phases of Trypanosoma cruzi (a flagellated protozoan 
parasite) infection in the human body − acute and chronic.  If diagnosis is prompt and treatment 
is successful, patients progress past the acute phase and either enter the asymptomatic 
indeterminate or symptomatic form of the chronic phase.  Some literature classifies the acute, 
chronic indeterminate, and chronic symptomatic stages as three separate phases as opposed to 
two (Telleria and Tibayrenc, 2017).  Of the individuals who develop clinical complications 
during the chronic phase, the three primarily affected body systems are the cardiovascular, 
digestive, and nervous system, respectively.  Scientists are unable to identify the reason 
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previously infected patients remain in the indeterminate stage indefinitely while others suffer 
severe illness. 
This review article explores recent etiologic studies, the life cycle of T. cruzi, effects of 
CD on humans, current medicinal practices such as diagnosis and treatment, and future 
challenges requiring further research.  A comprehensive exploration into previous and current 
research regarding forms of treatment is the specific focus.   
History  
 Carlos Chagas was participating in an anti-malaria campaign in 1908 located in Lassance, 
Minas Gerais, Brazil when a railroad engineer introduced him to kissing bugs containing the 
agent of CD – T. cruzi (Frederick et al., 2018).  Before this experience, Chagas had already 
studied T. minasense in monkeys.  However, by the age of 33, Chagas completed and published 
his research which incorporated the causative agent, vector, and human case studies of CD.  All 
three discoveries were made within five months at Manguinhos Institute under his professor and 
mentor Oswaldo Cruz who founded this institute (Telleria and Tibayrenc, 2017).  Chagas was a 
Brazilian clinician and researcher who contributed greatly to the scientific community’s 
knowledge of CD and was elected in 1929 as a member of the Committee of Hygiene of the 
Society of Nations, the forerunner of the World Health Organization, before his death in 1934 at 
the age of 56 (Moncayo, 2010).  Salvador Mazza, who characterized the three clinical stages of 
CD, and Cecilio Romanha, who identified the classic ocular edema symptom, were two other 
scientists notable for their contribution to the discovery of CD (Telleria and Tibayrenc, 2017).   
 Case number 1 of CD was found in a girl named Berenice, Carlos Chagas’ first patient. 
Her symptoms as described by Chagas in his 1909 article included edema, fever, and anemia.  
Lana et al. located Bernice at the age of 78 and restudied her case (Telleria and Tibayrenc, 2017).   
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She was asymptomatic and, after finding circulating T. cruzi in her blood, was found to have the 
indeterminant chronic form like the 75% of patients diagnosed with CD.   
 According to Telleria and Tibayrenc, interesting facts, myths, and theories have arisen 
throughout the study of CD.  For example, T. cruzi was initially but incorrectly associated to the 
goiter, which is now known to be a result of iodine deficiency not a pathogen (2017).  Many 
current scientists believe Charles Darwin was affected by and died from Chagas Disease after 
contracting the protozoan during his time on the Galapagos Islands (2017).  Lastly, DNA from 
the CL Brener strain of T. cruzi was the first to be sequenced, which was published in 2005. This 
strain has a 50% repetitive genome, which is 57% similar to the Trypanosoma brucei genome 
and 44% similar to the Leishmania major genome (2017).   
Epidemiology 
Latin American countries with the highest prevalence rate per 100 inhabitants of CD 
include Bolivia (6.1), Argentina (3.6), Paraguay (2.1), and Ecuador (1.4) (“Chagas disease in 
Latin America”).  However, countries with the greatest number of CD infected people consist of 
Argentina (1.5 million), Brazil (1.2 million), Mexico (0.88 million), and Bolivia (0.61 million) 
(see Appendix A for further epidemiological information).  Chagas disease is termed a neglected 
tropical disease, indicating a direct correlation between poverty and infection.  Poorer 
populations are most affected because triatomine bugs reside within cracks and holes of houses, 
beneath bark, and in chicken coops, rodent burrows, and dog cages.  With that said, the incidence 
rate of infection due to vector-borne transmission is much larger in Brazil (0.084) and Bolivia 
(0.081), while that of congenital transmission is largest in Paraguay (0.34), Belize (0.33), and 
Ecuador (0.32).  Per year, there are roughly 41,000 cases of vectorial transmission and 14,000 
cases of congenital transmission.  Coupled with the fact 6-8 million individuals are currently 
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infected with CD, this data suggests control methods have been overall successful but not 
absolute.  
In the United States, there have been 7 autochthonous vector-borne, 7 blood transfusion, 
and 6 organ donor related reported cases (Bern et al., 2011).  Autochthonous implies CD was 
spread from one infected individual to another via a vector in the same geographical area.  This 
occurrence is significant because it suggests the locations where suitable CD vectors are 
surviving their living conditions is expanding beyond solely Latin American countries. 
Nevertheless, these numbers are low due to the fact the United States has implemented vector 
control and blood screening protocols and is home to only 11 triatomine vector species, in 
comparison to over 100 species in South America (Bern et al., 2011).  Chagas disease infections 
in dogs and livestock have been reported in the southern US, most notably in the state of Texas, 
where 351 canine cases were described between 2013 and 2014 (Curtis-Robles et al., 2015).  
Roughly 300,000 immigrants infected with CD live in the United States (Longo et al., 2015).  Of 
the populations living in Andean countries, 25 million people are in danger of contracting the 
disease (Cura et al., 2017).   
Life Cycle of Trypanosoma cruzi 
The life cycle of T. cruzi has three stages − trypomastigotes, epimastigotes, and 
amastigotes (Carrea et al., 2016).  Trypomastigotes are the largest, followed by epimastigotes 
and amastigotes.  Unique structural features of T. cruzi are their kinetoplast (conglomerate of 
mitochondrial DNA situated near the nucleus), undulating membrane (associated with the 
flagellum to enhance locomotion), glycosome (specialized peroxisomes that perform carbon 
dioxide fixation, purine salvage, and pyrimidine synthesis, in addition to normal peroxisomal 
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functions), and acidocalcisome (elemental storage and osmoregulatory organelle) (Telleria and 
Tibayrenc, 2017).  Amastigotes lack both a flagellum and undulating membrane.  
The insect vector is the triatomine bug, or “kissing bug” (Order: Hemiptera, Family: 
Reduviidae).  The nickname is derived from the fact triatomine bugs are attracted to the human 
mouth and eyes region.  Kissing bugs’ propensity to bite near the mouth and eyes is not random 
because they smell the higher concentration of carbon dioxide.  Three common genera include 
Triatoma, Panstrongylus, and Rhodnius.  Living throughout the entire region between southern 
United States and southern Argentina, these insects exist in both dry and wet climates.  
The cycle begins when a triatomine vector, the kissing bug, ingests trypomastigotes from 
the blood of a mammalian host. A triatomine bug bite wound is visible and distinguishable from 
a typical insect bite such as from a mosquito because they are bigger, averaging a length of 1 
inch.  Inside the insect, epimastigotes form as trypomastigotes differentiate.  Epimastigotes 
replicate by binary fission in the small intestine (midgut) and then differentiate into metacyclic 
trypomastigotes in the large intestine (hindgut).  T. cruzi are referred to as stercoraria because of 
their posterior station development in triatomine bugs.  The mode of parasite transmission differs 
from salivaria species such as Trypanosoma brucei in tsetse flies, which have an anterior station 
development.  Next, the vector releases metacyclic trypomastigotes in their feces near the bite 
site on a mammalian host, which breaches the integument barrier through a cut, mucous 
membrane or conjunctiva, and results in infection.  In other words, the moment of human 
infection is not during the vector’s blood meal, rather when the mammalian host mechanically 
rubs the parasite into the open bite wound.  
Intracellular and extracellular stages occur when T. cruzi resides within the mammalian 
host - amastigotes occur intracellularly and trypomastigotes occur in the bloodstream but not 
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inside blood cells.  Inside human cells, the metacyclic trypomastigotes transform into 
amastigotes and replicate by binary fission.  Intracellular amastigotes are able to transform into 
trypomastigotes when the cell ruptures.  From this point, trypomastigotes may infect brain cells 
and muscle cells such as the esophagus, colon, and heart due to the fact this life cycle stage 
circulates in the bloodstream.  The cycle completes as the secondary host, a vector, bites the 
primary host, an infected mammal and contracts the protozoan pathogen, becoming infected (see 
Appendix B for T. cruzi life cycle diagram).   
While asexual reproduction occurs in triatomine bugs and sexual reproduction in humans, 
reservoir hosts may contract the parasite, display no signs of infection, yet transmit metacyclic 
trypomastigotes to humans.  In the western United States, woodrats, cayotes, racoons and skunks 
are common reservoir hosts, while in the eastern United States, racoons, armadillos, skunks, and 
opossums are common reservoir hosts (Bern et al., 2011).  Dogs are especially a concern for 
disease prevention because they are domestic and have large populations.  
Prevention 
Organ transplants, blood transfusions, laboratory accidents, and oral (foodborne), 
placental or congenital transmission are mechanisms of transferring CD other than via vector-
borne transmission (Pérez-Molina et al., 2018).  Vector control has been the primary mechanism 
of Chagas Disease prevention.  This type of control includes the use of insecticides in infested 
homes and buildings.  Vector control implementation also encourages the use of bed nets, insect 
repellent, and appropriate clothing.  National control programs in developed countries have 
reduced the prevalence of CD through the enactment of blood screenings.  However, the 
financial burden in several Latin American countries is too immense to enforce preventative 
measure beyond blood screenings.  The yearly global expenditure on CD is $627 million, of 
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which the US spends $118 million (Meymand et al., 2017).  Regarding chronically diseased 
individuals, antiparasitic treatments are the most promising route of research because they have 
the potential to be a turning point in the trajectory of the disease, which means developing a 
newer and more effective drug or vaccine is essential. 
Medical Indications 
Initially, due to the small size of the protozoan, an acute Chagas infection is 
asymptomatic.  When they do occur, symptoms of the acute phase include fever, malaise, 
swollen lymph nodes, and inflammation at the infection site. The Romaña sign, named after 
Cecilio Romanha, is the unilateral swelling of the eyelid and a telltale sign of CD. Infants who 
congenitally contract the disease often show signs of hypotonia – reduced muscle tone –, fever, 
anemia, and hepatosplenomegaly − enlargement of both spleen and liver (Rassi et al., 2010). 
Life-threatening symptoms such as myocarditis and meningoencephalitis of the acute phase 
occur in less than 1% of cases.  The incubation period post inoculation is 1-2 weeks and clinical 
manifestations subside within 4-8 weeks.  Once infected with CD, 100% of untreated and 20% of 
treated people possess the disease indefinitely (Longo et al., 2015).  Therefore, following this 
phase, patients advance to the chronic phase.  The majority of these patients remain in the 
asymptomatic determinant stage, while 30-40% of untreated and 6-8% of properly treated people 
become afflicted years or decades later with symptoms of the chronic phase.  Cardiomyopathy 
and megaviscera are two frequent problems associated with the organs affected by the 
symptomatic chronic phase.  The heart and visceral organs represent 14-45% and 10-21% of the 
chronic symptomatic instances, respectively (Pérez-Molina et al., 2018).  
Unexpected death is the foremost concern for patients with amastigotes replicating in 
their heart cells, which disrupts the conduction system and myocardium.  Atrioventricular 
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blocks, tachycardia, bradycardia, sinus node dysfunction, and left ventricular aneurysms are 
usual causes of congestive heart failure for people with CD, contributing to poor prognoses.  
Chronic Chagas cardiomyopathy (CCC) has a 60% death rate due to arrhythmia and, of the 
children who die from heart disease in Latin American countries, 70% are caused by CCC 
(Carvalho et al., 2017).  Furthermore, there is a stronger correlation between male patients and 
myocardial fibrosis in comparison to female patients (Assunção et al., 2016).  
Gastrointestinal complications as a result of CD are widespread in the southernmost part 
of South America as opposed to the rest of Latin America, although it is present there as well.  
Megaesophagus and megacolon put patients at risk for esophageal cancer and persistent 
constipation, respectively.  Specifically, the sigmoid colon and rectum become enlarged in the 
severe forms of megacolon, leading to abdominal distention, regurgitation, and bowel 
obstruction.  About 5-20% of patients who experience myocardiopathy also have harmful 
gastrointestinal expressions.  Furthermore, neurological involvement exists in up to 10% of cases 
and presents as neuropathy or polyneuropathy.  Roughly 2.7 people suffering from CD induced 
cardiomyopathy undergo an ischemic stroke each year (Carvalho et al., 2017). 
Overall, during symptomatic chronic CD, cardiac, gastrointestinal, and neurological 
complications are common.  Amastigotes may be found in the myocardium, causing congestive 
heart failure, or in alimentary canal organs such as the esophagus, small intestine, and colon, 
which causes megaviscera.  Less commonly, the brain and spinal cord are infected with 
amastigotes, resulting in meningoencephalitis or an ischemic stroke.  Lastly, immunosuppressed 
patients are at risk for an exacerbated infection level and thus more likely to undergo symptoms 
such as meningoencephalitis and lesion formation in the central nervous system.  
Pathogenesis 
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Chagas disease pathogenesis remains a subject requiring ample research due to genetic 
variability of the T. cruzi parasite and of the primary and secondary hosts.  A pressing question 
for doctors and scientists studying CD is why chronic phase symptoms normally come about 
decades after persisting in a latency stage.  
 An inflammatory response and rapid antibody production are accompanied by acute 
phase infection (Pérez-Molina et al., 2018).  Amastigotes inhabit tissues such as smooth, cardiac, 
and skeletal muscle, the brain, red blood cells, macrophages, and gonads.  For example, the 
tumor necrosis factor alpha (TNF-𝛼) and interferon gamma (IFN-𝛾) of the innate immune 
response, which are proinflammatory cytokines, become activated.  IFN- 𝛾 is essential for 
controlling parasite infections, but it also has a tendency to be overproduced, leading to the 
synthesis of reactive oxygen species and nitric oxide synthases.  
 The chronic phase of CD is identified by levels of inflammation.  Specific T. cruzi strains 
produce varying levels of disease in people because certain strains are more virulent than others.  
In total, more than 6000 T. cruzi strains have been identified, of which strains TcI through TcV 
are the most common in relationship to CD (Brenière, Waleckx, & Barnabé, 2016).  As stated 
previously, pathogenesis in the chronic phase is still an enigma waiting to be explained.  
However, in addition to the cytokines produced during the acute phase via CD4+ T lymphocytes, 
cytotoxic processes are employed during the symptomatic chronic phase via CD8+ T 
lymphocytes (Teixeira et al., 2011).  Briefly, CD4+ T cells, or T helper cells, are involved with 
innate immunity and are activated by major histocompatibility complex II (MHC II) molecules 
on antigen-presenting cells (APCs) (Janssen et al., 2003).  Their main functions are cytokine 
secretion and activation of B cells and macrophages.  CD8+ T cells, or killer T cells, are involved 
with adaptive immunity and are activated by MHC I molecules on APCs.  Their main functions 
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are secretion of cytotoxic granules and defense against intracellular parasites.  Scientists believe 
overactivation of CH8+ T cells is the reason for severe tissue damage such as megaviscera and 
cardiomyopathy during the symptomatic chronic phase (Pérez-Molina et al., 2018).  In contrast, 
the indeterminate chronic phase may be referred to as a host-parasite equilibrium (Andrade et al., 
1997).   
Diagnosis 
Diagnosis of CD varies with the infection phase of the parasite and, occasionally, with 
the mechanism by which the disease was acquired.  Ideal diagnosis is early and confirmed by 
multiple methods.  Wright-Giemsa stained blood, which stains human erythrocytes pink and 
human leukocytes purple, is sufficient enough for an acute phase diagnosis (Longo et al., 2015).  
Additionally, trypomastigotes may be seen by examining freshly coagulated blood under the 
microscope. 
The method of choice for diagnosing a congenital Chagas infection is called 
microhematocrit, which ascertains the ratio of volume of red blood cells to the volume of total 
blood, allowing for relative quantification.  Furthermore, xenodiagnosis introduces the blood 
from a patient being tested for the disease into a laboratory-bred triatomine insect and analyzes 
the insect’s excrement over a period of two months to determine if the original blood sample 
contains the parasite. Xenodiagnoses is a suitable diagnostic method for infants who congenitally 
obtained chronic CD.  If an infant has a negative test result for the presence of trypomastigotes 
and his/her mother was infected at the time of birth, doctors recommend that the infant be tested 
for anti-T. cruzi IgG at nine months. At this stage of development, babies no longer have 
maternal antibodies.  Therefore, retesting the infant is important in ensuring he/she has 
developed a sufficient number of appropriate antibodies.  Polymerase chain reaction (PCR) is 
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another technique used to diagnosis infants who are at risk of being infected due to congenital 
transmission.  The process of PCR requires three steps – denaturing, annealing, and extending. 
Denaturing is the separation of DNA at a high temperature (94C), annealing is the attachment of 
DNA primers to the resulting single-stranded DNA at a low temperature (54C) and extending is 
the synthesis of a new strand of DNA at a medium temperature (72 C).  PCR is preferred over 
microscopic visualization because it is more sensitive and detects even the slightest existence of 
a parasite’s DNA in human blood.   
Those with a chronic phase infection must undergo two of the following diagnostic 
procedures for a confirmatory diagnosis: serological test of IgG, PCR, enzyme-linked 
immunosorbent assay (ELIZA), indirect immunofluorescence, or hemagglutinin assay.  The 
necessity for extensive clinical tests is because the parasite is too small during the chronic phase 
to be detected by microscopy (Edimar et al., 2017).  An electrocardiogram (ECG) test typically 
accompanies the former assays in diagnosing symptomatic chronic CD. Positive results from an 
ECG include sinus tachycardia and low QRS voltage. 
Prognosis 
As stated before, the incubation period after vector-borne transmission is 1- 2 weeks.  
The incubation period is 1- 6 weeks following blood transmission, and 2 days to 3 weeks 
following oral transmission (2017).  There are 5 classifications for patients with CCC.  Type A is 
positive for T. cruzi.  Type B1 is positive for heart disease and negative for ventricular 
dysfunction.  Type B2 is positive for heart disease and ventricular dysfunction but does not 
indicate heart failure.  Type C is positive for heart disease, ventricular dysfunction, and heart 
failure.  Lastly and most critically, type D patients have extremely advanced and unmanageable 
heart failure. 
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Since CCC is the worst manifestation of CD, the mortality prognosis for these patients is 
12% after 1 year, 35% after 5 years, and 60% after 10 years.  Yet, patients diagnosed with type D 
have less than a 10% survival rate after a year.  Accurate predictors of mortality are left 
ventricular systolic function, cardiomegaly or ventricular tachycardia (Rassi et al., 2010).  
 
 
Treatment 
The two anti-parasitic medications for acute CD are benznidazole and nifurtimox.  
However, only the former is approved by the U.S. Food and Drug Administration (FDA) because 
the latter is more toxic and must be taken in larger doses and for a longer period of time 
(Menezes et al., 2012).   
Benznidazole (Bnz) is the first-line treatment due to its less harsh side effects, which are 
a result of an enzyme catalyzed reduction of the nitro functional group producing metabolites 
(Molina et al., 2015).  Rashes are frequent side-effects, but dermatitis, fever and/or 
lymphadenopathy − disease of the lymph nodes − are less common but significant enough that 
termination of the medication is suggested if they occur.  The rarest side effect is bone marrow 
suppression, which warrants immediate termination and usually hospitalization.  General and 
less serious complications include headache, anorexia, and insomnia.  Infected children and 
adults should take 5-10 mg/kg per day for 60 days (Rassi et al., 2010).  Of the CD patients who 
were administered Bnz during a case study in Spain, 22% terminated the course of treatment 
within 30 days due to severe side effects and 30% ended treatment before the end of the study 
(Pérez-Ayala et al., 2011). Women have a higher hypersensitivity to Bnz, an unfortunate fact 
since females are at a greater risk of infection. 
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Nifurtimox interferes with pyruvic acid synthesis and carbohydrate metabolism. 
Approximately 70% of patients using this medication experience gastrointestinal side effects.  
Other unwanted neurological effects may include irritability, tremors, or insomnia.  Rare but 
more serious physiological side effects involve the peripheral nervous system.  These may 
include pressure on peripheral nerves, polyneuropathy, or neuritis.  Infected children should take 
15 mg/kg and adults 8-10 mg/kg daily for 60-90 days.   
Overall, 80-90% of patients are cured from the acute phase by treatment with 
benznidazole or nifurtimox at the earliest onset.  Recent studies suggest that either of these drugs 
may successfully treat children with chronic CD due to early exposure.  For example, these drugs 
cure 8% of adults and 62% of children at the asymptomatic indeterminant phase (Menezes et al., 
2012).  The efficacy of both drugs is higher in children than adolescents and adults.  The benefit 
of taking either anti-trypanosomal treatment for people over the age of 5 has not been 
demonstrated.  
The major courses of treatment for patients with the chronic form is slowing the 
progression of the disease and managing symptoms.  For instance, a symptomatic chronic patient 
experiencing atrioventricular blocks may need a pacemaker.  Ventricular arrhythmias as result of 
CCC are often treated by doctors with the amiodarone drug, which blocks abnormal cardiac 
electrical signals, reducing the chances of an irregular heartbeat (Stein et al., 2018).  For 
individuals with refractory heart failure, cardiac transplantation is the ideal course of treatment.  
Fundoplication is a surgical procedure that wraps the upper portion of the stomach around the 
lower portion of the esophagus and prevents gastro-esophageal reflux.  Nitrates and nifedipine 
are two drugs that some medical professionals administer to gastrointestinal CD patients to help 
lower esophageal-sphincter relaxation and assist in directing food and liquids past the esophagus.  
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A fiber rich diet, intake of ample liquids, and consumption of laxatives are appropriate methods 
of treating colon motility dysfunction − constipation, diarrhea and/or abdominal cramping.  Fecal 
impaction may occur in later stages of colon dysfunction and may require surgery to manually 
dislodge contents.  
Socioeconomic Challenges of the Disease 
Triatomine bugs are prevalent in rural and impoverished areas.  Of the neglected tropical 
diseases, CD is one of the costliest (Nunes et al., 2013).  This makes management of the disease 
difficult for undeveloped and developing countries and low-income households.  In 2013, the 
global expenditure was $7.19 billion per year, which was spent on research, medical treatments, 
and diagnostic techniques (2013).  While this quantity has halved since 2013, CD is still 
responsible for huge economic hindrances.  The United States and Canada are responsible for 
providing 10% of the yearly funds needed to fight against CD.   
Future Research Areas and Opportunities 
Three pressing and unanswered questions about Chagas Disease include (1) the 
pathophysiology of chronic Chagasic cardiomyopathy, (2) role of autoimmunity in pathogenesis, 
and (3) the relationship between the severity of a CD infection and the virulence of the T. cruzi 
strain.  Researching these topics could ultimately lead to the invention of a suitable vaccine or, at 
the very least, a better understanding of the diversity of the protozoan and the effects it induces 
in the human body.  
Standardized animal models that better represent the effectiveness of new drugs need to 
be developed.  Training healthcare professionals to treat CD patients and relocating them to 
endemic areas of Latin America has been a challenge but is imperative, especially because long-
term care is required for all previously infected patients.  Developing sustainable preventative 
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regulations, devising a plan to make diagnostic equipment and treatment available since CD is a 
poverty-related infection, creating more advantageous and affordable medications, and 
conducting epidemiology studies are also sought-after achievements.  
Chagas Disease Overview 
In short, Chagas disease remains an important area of research due to the number of 
affected lives each year in Latin America.  Since its discovery, the number of annual deaths has 
significantly decreased, but a lot of work still needs to be done in order to develop a vaccine or a 
more acceptable medication.  The acute phase is better understood in terms of symptoms, 
physiology, and predictability compared to the chronic phase.  Advanced diagnostic techniques 
have been devised for CD.  Diagnosing an infected patient is able to be done fairly quickly and 
accurately.  However, the problem rests in the fact numerous patients do not have access to 
medical care and, when they do, are limited.  Early detection of the disease is crucial for even a 
remotely positive prognosis.  The two anti-parasite medications, benznidazole and nifurtimox, 
have an increased efficacy when distributed at the earliest onset.  As time passes, adult 
generations are growing older and, since current CD drugs have unknown effects in the elderly, 
the hope of success in the abundant clinical trials being conducted is high. 
Current Treatment Research 
 Since the two forms of Chagas Disease treatment − benznidazole (Bnz) and nifurtimox 
(Nfz)− have severe side effects and limited efficacy, research into new forms of medication is 
imperative.  Previously tested medications include ketaconazole, posaconazole, ravuconazole, 
E5700, amiodarone, K777, aryl-imidamine, and allopurinol (Menezes et al., 2011).  While these 
experiments had promising results, they did not yield a cure.  In other words, they lead to 
symptom alleviation, reduced parasite load, and improved organ function, but did not provide a 
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cure on the organismal level.  Research into the development of novel pharmaceutical 
medications is time-consuming and expensive, hence the numerous emerging low dose Bnz 
combination therapy experiments being conducted.  In addtition, various vaccine options are also 
being explored, but success is limited due to the antigenic variation ability of T. cruzi.  
Drug Combination Therapies 
Thiazole and furan compounds.  In an experiment testing the effects of drug 
combinations, three compounds, when individually mixed with Bnz, showed various results.  
Thiazole compound 2, furan compound 3, and thiophene compound 4 were additive, synergistic, 
and antagonistic against T. cruzi epimastigotes, respectively (Aguilera et al., 2018).  Compound 
4 was removed from research because the in vitro studies disproved its effectiveness for 
treatment of CD in combination with Bnz.   
The results of the in vivo phase of this experiment, which involved intraperitoneally 
injecting 5,000-10,000 blood trypomastigotes in male mice, were positive.  The experimental 
groups were orally treated with either compound 2 alone, compound 2 and Bnz, compound 3 and 
Bnz, or Bnz alone.  The dosage schedule of compound 2 alone (50 mg/kg b.w/day), Bnz alone 
(5, 10, 25, 50, and 100 mg/kg b.w/day) and combination of compound 2 (50 mg/kg b.w/day) and 
Bnz (5 mg/kg b.w/day) was three cycles of five consecutive day administrations with two day 
intervals, while the dosage schedule of compound 3 (50 mg/kg b.w/day) and Bnz (10 mg/kg 
b.w/day) was 15 consecutive day administrations (2018).  The compound 2 and Bnz 
experimental group overcame the second parasitemia infection peak at day 37, maintained 100 
percent survival at the end of the 60-day trial, and decreased in the number of anti-T. cruzi 
antibodies.  This is significant because the survival rates of compound 2 alone and the control 
group after 60 days were 83 percent.  Lastly, the compound 3 and Bnz experimental group 
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shifted the first maximum parasitemia infection peak from day 21 to day 30, abolishing the 
second peak, maintained 100 percent survival, and had lower anti-T. cruzi antibody levels.  This 
is significant because the survival rate of the control group after 60 days was 85 percent.  In 
comparison to 2 plus Bnz, 3 plus Bnz demonstrated the best outcome against T. cruzi due to its 
synergistic effect, lowering the first and completely eliminating the second parasitemia peaks.  In 
the future, these chemical compounds may prove to potentiate the efficacy of Bnz and lessen its 
side effects through use of smaller dosages.  Pharmacological research, modifying the treatment 
administration schedules, is currently being conducted. 
Vitamins.  Cyanocobalamin or vitamin B12 (Vit B12) has antiparasitic properties when 
combined with Bnz and used to treat T. cruzi infected mice.  Initially, in vitro studies using Vit 
B12 on a culture of T. cruzi epimastigotes resulted in an indirect relationship between 
concentration of Vit B12 and parasitemia levels (Ciccarelli et al., 2012).  However, the decreased 
growth rate lasted for only a short period of time subsequent to treatment, indicating a reversal of 
the antiparasitic activity of Vit B12.  
In vivo antiparasitic activity was tested despite in vitro method results because the short 
timeframe of efficacy may have been attributed to culture instability.  Mice were 
intraperitoneally infected with 5,000 blood trypomastigotes and treated five days later.  Groups 
1-5 were administered Vit B12 alone (1.5 mg/kg b.w/day), Vit B12 (1.5 mg/kg b.w/day) plus Vit C 
(1.5 mg/kg b.w/day), Bnz (0.75 mg/kg b.w/day) alone, a combination of the three compounds, 
and a vehicle control, respectively (Ciccarelli et al., 2012).  The dosage schedule for all groups 
was two cycles of 5-day administrations with a two-day interval.  The parasitemia levels on day 
13 for groups 1-5 were 2.23 x 106, 1.26 x 106, 1.43 106, 1.33 106, and 4.18 106 parasites/ml, 
respectively.  Since group 5 was the control, these results indicated that all experimental groups 
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experienced a lower parasitemia level due to the treatment, but Bnz alone and Bnz combined 
with both vitamins had the lowest infection levels.  Moreover, no group had a 100 percent 
survival rate.  The control had zero percent survival, Bnz alone and Bnz plus both vitamins had 
70 and 80 percent survival, respectively.  Therefore, considering both parasitemia levels and 
percent survival, group 4 treated with Bnz plus Vit B12 and Vit C displayed the most optimal 
results. 
 During a recent study conducted in the same laboratory as the previous combination 
assay with Vit B12 and Vit C, a team first focused on Vit C’s antioxidant and pro-oxidant 
activities and then tested its ability to potentiate antiparasitic mechanisms of Bnz (Puente et al., 
2018).  When present at physiological levels, Vit C acts as an antioxidant, neutralizing free 
radicals. When present at high levels due to pharmaceutical intervention, Vit C is catalyzed by 
metallic ions and acts as a pro-oxidant, generating reactive oxygen species (ROS).  The authors 
hypothesized that Vit C acts as a pro-oxidant inside the parasite where the concentration is 
higher due to a smaller cell size but as an antioxidant inside the human body where the 
concentration is lower due to a larger cell size. 
Three life cycle forms of T. cruzi were tested during the in vitro stage − epimastigotes, 
trypomastigotes, and amastigotes (Puente et al., 2018).  The results of Vit C alone versus Bnz 
alone were similar between the three parasitic forms.  Trypomastigotes, the infective stage of T. 
cruzi, was used in the in vivo phase.  Mice were intraperitoneally injected with 5,000 
trypomastigotes and treated with either Vit C (1.5 mg/kg b.w/day), Bnz (0.75 mg/kg b.w/day), a 
mixture of both, or a vehicle control seven days later.  
The results indicated that Vit C serves as a pro-oxidant when given alone and as an 
antioxidant when given in combination with Bnz.  However, it does not play both roles of pro-
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oxidant against T. cruzi and antioxidant for the host because similar lysis percentages where 
determined for the combination and Bnz alone experimental groups.  The minimal concentration 
of Vit C alone needed to employ cytotoxic effects is 2,500 uM.  Conclusively, this study 
suggests that the presence of Bnz reduces the effects of Vit C to merely antioxidant by 
eliminating its pro-oxidant mode of action.  
 Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are harmful 
substances present in individuals infected with CD.  Bnz and Nfx, when metabolized, also 
produce ROS and RNS, amplifying the toxicity experienced by the patient and leading to multi-
organ inflammation, a common symptom of CD.  Another study, published by a different 
laboratory but in the same month as the previous article, also attempted to reduce the oxidative 
environment, by performing a combination experiment utilizing Bnz (Providello et al., 2018).  
Ascorbic acid (AA) or vitamin C (Vit C), an antioxidant, was the medication used in 
combination with Bnz.  Male murine models were used and intraperitoneally injected with 
10,000 blood T. cruzi trypomastigotes.  Five groups were formed and included (1) control 
without infection nor treatment (2) infected control without treatment, (3) infected and treated 
with Bnz (10 mg/kg b.w/day), (4) infected and treated with AA (7 mg/kg b.w/day), and (5) 
infected and treated with AA and Bnz (AA+Bnz10; at7:10 mg/kg b.w/day).  Drugs were 
administered for 15 consecutive days starting two days subsequent to infection. 
In vivo research determined decreased parasitemia levels in the AA+Bnz10 group 
compared to the AA and Bnz alone experimental groups (Providello et al., 2018).  Additionally, 
the mice who were administered both AA and Bnz had lower intracellular ROS, diminished 
cardiac parasitemia and inflammation, and eliminated hepatic inflammation at the end of the 17-
day protocol.  The findings of this drug association study suggest AA may be another potential 
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chemical compound that, when combined with Bnz, protects against T. cruzi infections by 
minimizing intracellular oxidative damage and reducing inflammation symptoms.  During 
clinical trials, Bnz plus AA improves cardiac arrhythmia symptoms of chronic CD patients, but 
additional research is needed.  
Pentoxifylline.  The chronic form of Chagas disease is predominantly attributed to the 
disease’s morbidity and mortality rates because it causes Chagas cardiomyopathy.  Symptoms 
associated include abnormal heartbeats, altered electrocardiogram (ECG) results, and 
myocardium inflammation, as well as high and constant levels of parasitemia.  Worsening 
fibrosis gives rise to congestive heart failure and, in several cases, unexpected death.  
Nitric oxide (NO) and tumor necrosis factor (TNF) are important components of both 
acute and chronic phases of CD.  In moderate concentrations, the former possesses trypanocidal 
functions and the latter binds to G protein-couple serpentine receptors, inducing the upregulation 
of inducible NO synthase (iNOS), which catalyzes the formation of NO (Silva et al., 2003). 
However, persistent high concentrations of NO have been attributed with the development of 
CCC. Infliximab is an anti-TNF drug and, when given to acute CD patients, slowed and reduced 
cardiac tissue damage but did not interfere with parasitemia controls.  Bnz is used to lower 
parasite loads.  For patients who do not receive early treatment, CCC develops, meaning Bnz is 
unable to protect against deteriorating health due to the establishment of immunological 
imbalances.  In short, administered Bnz and naturally synthesized NO and TNF work together to 
protect the body against a T. cruzi infection by initiating an appropriate inflammatory response 
and attacking the protozoan.  Yet, when Bnz is not administered early, NO and TNF are not 
sufficient enough to treat the parasite infection and their effects actually become harmful due to 
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prolonged inflammation.  Pentoxifylline (PTX) is an immunoregulator that, when combined with 
Bnz, has shown to alleviate and reduce these symptoms of CCC (Silva et al., 2003).  
The Colombian strain of T. cruzi was used in a chronic murine model and 100 blood 
trypomastigotes were intraperitoneally injected.  Eighty percent of the infected mice survived 
with treatment until 120 days post infection, surpassing the acute phase.  The first presence of 
blood trypomastigotes indicates the beginning of the acute phase and a drop-in blood 
trypomastigotes after a high elevation indicates the beginning of the chronic phase.  From 
parasitemia assays, day 14 and 90 were deemed the onset of the acute and chronic phases, 
respectively (Vilar-Pereira et al., 2016).  During the chronic phase, from 120 to 150 days post 
infection, mice were orally treated with either (1) Bnz alone (25 mg/kg b.w/day), (2) PTX alone 
(20 mg/kg b.w/day), or (3) Bnz plus PTX.  On day 150, all infected mice that received treatment 
survived while only 80 percent of the vehicle control group survived.  
Results of this in vivo study supported the initial hypothesis which stated suboptimal 
levels of Bnz in combination with PTX would not only lessen CCC symptoms of fibrosis and 
inflammation, but that the effects would persist past termination of treatment.  Notable outcomes 
of the Bnz plus PTX group included minimized atrial flutter – rapid atrial chamber pumping – 
and ameliorated second-degree atrioventricular blockages (Silva et al., 2003).  Additionally, 
reversal of the ECG QT wave abnormality, which is described as a frequent cause of death in 
CCC patients, and rapidly decreased NO and TNF production was evidenced just in the 
combination therapy group.  These finding do not suggest the therapies completely eliminated 
levels of parasitemia and restored health, rather Bnz plus PTX acted as an adjuvant by 
normalizing immune system responses and suppressing elevated inflammation.  Clinical trials 
are the next step in research based on the fact the infected murine model experienced an 
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improved prognosis after treatment with 25 percent of the normal dose of Bnz in combination 
with the already clinically proven benign drug PTX (Vilar-Pereira et al., 2016).  
Vaccinations 
80 kDa prolyl oligopeptidase.  A recent experiment isolated a T. cruzi 80 kDa prolyl 
oligopeptidase (Tc80) gene from strain RA and cloned it into the pcDNA3.1 plasmid.  Tc80 is 
the virulent protozoan gene responsible for breaking down extracellular matrix components and 
establishing easy access into the host’s tissues and cells (Bivona et al., 2018).  The delivery 
system was Salmonella enterica bacteria, the restriction sites were HindIII and XhoI, and a 
murine model was utilized. Group I intramuscularly received rTc80 (10 ug) with 
oligodeoxynucleotides CpG 1826 (10 ug) and group II orally received weakened Salmonella 
with a Tc80 plasmid (1x109 CFU/mouse).  Group III was administered a combination of the 
previous two and group IV mice, the control, were intramuscularly given phosphate-buffered 
saline (PBS) and CpG-ODN (10 ug) and orally given weakened Salmonella with a blank 
plasmid.  Four doses were administered with three 10-minute intervals. 
Functions unique to the immunized mice included counterbalanced parasitemia levels, 
Tc80 enzyme inhibition, and trypomastigotes cell lysis.  Mice treated with weaken forms of the 
Salmonella Tc80-gene carrying plasmids, groups I and II, possessed the highest percent survival, 
representing the significance of cell-mediated immunity with active antigens as opposed to 
humoral-mediated immunity with passive antibodies (Bivona et al., 2018).  While antibiotic 
responses are needed during onset of acute CD, cytotoxic responses are essential in order to 
prevent the long term, lethal consequences accompanying chronic CD.  Therefore, the authors’ 
hypothesis stating Tc80 is an effective gene target for the development of a novel vaccine 
fighting CD infections was supported. 
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Recombinant enolase.  Another study isolated recombinant enolase (rTcENO) and its 
gene (pBKTcENO) from T. cruzi strain H8 (Arce-Fonseca et al., 2018).  In glycolysis and 
gluconeogenesis, intracellular enolase uses either magnesium or manganese to convert 2-
phosphoglycerate into phosphoenolpyruvate and water.  On the cell surface of pathogens, 
enolase is also a receptor, hence its utilization as a potential vaccine target.  Protein and DNA 
vaccines were tested in two experiments.  During the first, mice were intraperitoneally 
immunized with rTcENO (10 ug) or the PBS control.  During the second, mice were 
intramuscularly injected with pBKTcENO (100 ug) or the DNA vector control.  
Notable results included the presence of antibodies against epimastigotes after both types 
of immunization.  However, 75% of the rTcENO-immunized mice lived compared to the PBS 
control while none of the DNA vector-immunized mice lived compared to the DNA vector 
control (Arce-Fonseca et al., 2018).  Moreover, IL-2 and IFN-gamma production increased only 
after rTcENO vaccine deliverance.  IL-2 and IFN-gamma are released in response to Th1 and IL-
4, IL-5, and IL-10 are released in response to Th2.  Th1 and Th2 cell responses play a role in 
immunoglobulin synthesis, a process necessary in the removal of intracellular and extracellular 
parasites, respectively.  Together, these findings suggest rTcENO vaccine efficacy and 
pBKTcENO vaccine inefficacy against acute T. cruzi infections, laying the foundation for further 
research.  
Amastigote surface protein-2. The most recent publication exploring vaccinations for T. 
cruzi infections is by Ribeiro et al., which studied the effects of adenovirus expressing 
amastigote surface protein-2 (AdASP-2) injected into the tibialis anterior muscle on mice livers 
(2019).  The groups used during this study included group 1 (50 L vehicle control), group 2 
(150 T. cruzi blood trypomastigotes of Y strain and 50 L vehicle control), group 3 (50 L of 
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AdASP-2), and group 4 (150 T. cruzi blood trypomastigotes of Y strain and 50 L AdASP-2). 
All mice were subcutaneously infected and intramuscularly immunized (2019).  
Data collected during this experiment was the gene expression of nine substances 
associated with the immune system and located in the liver   – COX-2, TNF, TNF-𝛼, iNOS, 
cytochrome c, caspase-3, TLR4, IL-6, and IL-10 (Ribeiro et al., 2019).  After histological, 
genetic, and statistical analysis of acute CD infections, TNF-𝛼, iNOS, TLR4, and IL-10 were 
shown to be vital inflammatory cytokines that control infection levels. On the other hand, the 
anti-inflammatory apoptotic pathway via cytochrome c and caspase 3 was not initiated as a result 
of the AdASP-2 vaccine (2019).  
In summary, AdASP-2 removed trypomastigotes after a sublethal exposure and triggered 
tissue regeneration.  In regard to Chagas disease eradication efforts, vaccine AdASP-2 shows 
promising results.  
Unknown Impact on Latin American Countries  
 Telleria and Tibayrenc, in their book titled American Trypanosomiasis: Chagas Disease: 
One Hundred Years of Research, discuss two reasons for Chagas Disease being regarded as 
silent (2017).  Firstly, the heart and digestive symptoms of the chronic stage often manifest long 
periods of time after the initial infection, leaving patients unaware of their illness for several 
years and even decades.  Secondly, the social implications associated with CD foster literal 
silence in both endemic and nonendemic populations.  For instance, poverty, economic 
instability, poor living conditions, and political distress are factors resulting in and caused by 
Chagas disease.  Uneducated locals residing in mud huts of endemic regions that lack strong 
political governments and influence are most at risk (2017).  
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The financial burden of CD and the economic crisis most Latin American countries 
endure also contributes to a lack in prospective cohort studies as well as retrospective case 
studies.  A prospective study follows a patient or group of patients from before the onset of 
infection over a long period of time while a retrospective study traces a symptomatic patient or 
group of patients backwards to examine factors leading to infection.  Since the former type of 
experiment is more controlled and contains less opportunity for bias, the results yield accurate 
epidemiological rates and risk factors in comparison to the latter type of experiment.   
A cohort study by Pérez-Ayala et al. was conducted in Madrid, Spain from 2003 to 2009 
(2011).  Throughout the 7-year study, 1146 and 337 Latin American immigrants were screened 
by serology and PCR, respectively.  Positive results were seen in 31% of the former and 61% of 
the latter.  After further investigation, 97% were from Bolivia, 68% were female, and the 
majority were between the ages of 30 and 40 (2011).  A 2009 case study was conducted on a 47-
year-old man in the United States.  He initially presented to the American hospital with 
complaints of laterally radiating abdominal pain and constipation that was intermittent for 15 
years but became severe 5 weeks’ prior.  The patient was born in Central America, immigrated to 
the US twenty-five years before this hospital visit, and frequently travelled to his birth country.  
Subsequent to extensive clinical investigations and tests, he was diagnosed with Chagas disease 
due to a chronic T. cruzi infection (Isselbacher et al., 2010).  
Chagas disease research such as the cohort study in Spain and the case study in the US 
not only reinforce the expansion of the disease and its challenging diagnosis but suggest an 
unknown severity in Latin America.  The examined participants from Spain and the patient from 
the US all immigrated from Latin America, where their infection was acquired and where there is 
a scarce supply of similar studies being conducted.  
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The lack of both prospective and retrospective studies combined with the fact lower 
socioeconomical classes are most affected suggests that an accurate CD prevalence rate is 
unknown and likely higher than reported.  
Conclusion 
Over the span of 110 years, incredible progress has been made in regard to minimalizing 
Chagas disease and its negative impact on Latin American communities.  This success was 
initiated in 1909 by Carlos Chagas who identified the agent (T. cruzi), vector (kissing bugs), and 
clinical manifestation (cardiac, visceral, and nervous) of CD within a 5-month timeframe.  Other 
notable achievements were the discovery of the T. cruzi life cycle, determining the metacyclic 
trypomastigote infective stage and the intracellular amastigote diagnostic stage, prevention 
techniques such as vector control and screening of blood donation products, pharmaceutical 
treatments of benznidazole and nifurtimox, and acute and chronic phases of infection.  
Significant research into drug combination therapy as well as vaccinations has been 
conducted.  In low dose combinations with Bnz, thiazole and furan compounds delayed the onset 
of acute parasitemia spikes and lowered the concentration of anti-T. cruzi antibodies, Vit C had a 
reduced mode of action to merely antioxidant, ameliorating the negative impacts of ROS, and 
PTX lowered the presence of fibrosis and inflammation in CCC patients.  The vaccine efforts of 
rTc80 indicated lower parasitemia levels and trypomastigote cell lysis, while rTcENO showed 
the production of T. cruzi antibodies, and AdASP-2 suggested tissue regeneration and removal of 
trypomastigotes. 
Considering the high volume of promising research yet deficiency of funding for further 
explorations, CD has not been eradicated.  Additional factors contributing to the current 
prevalence of CD consist of the T. cruzi antigenic variation ability, existence of an unknown 
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number of individuals with an asymptomatic indeterminant phase of infection, expansion of 
suitable living environments for kissing bugs into the southern US, and limited quantity of 
prospective and retrospective studies available for review.  
  
 REVIEW OF CHAGAS DISEASE 
 
31 
References 
Aguilera, E., Varela, J., Serna, E., Torres, S., Yaluff, G., Bilbao, N. V. de, … González, M.  
(2018). Looking for combination of benznidazole and Trypanosoma cruzi-
triosephosphate isomerase inhibitors for Chagas disease treatment. Memórias Do Instituto 
Oswaldo Cruz, 113(3), 153–160.  
Andrade, S. G., Wenthold, R. J., Ferrans, V. J., Sadigursky, M., Andrade, Z. A., & Hilbert, S. L.  
(1997). The Indeterminate Phase of Chagas’ Disease: Ultrastructural Characterization of 
Cardiac Changes in the Canine Model. The American Journal of Tropical Medicine and 
Hygiene, 57(3), 328–336.  
Arce-Fonseca, M., González-Vázquez, M. C., Rodríguez-Morales, O., Graullera-Rivera, V.,  
Aranda-Fraustro, A., Reyes, P. A., … Rosales-Encina, J. L. (2018). Recombinant Enolase 
of Trypanosoma cruzi as a Novel Vaccine Candidate against Chagas Disease in a Mouse 
Model of Acute Infection. Journal of Immunology Research, 2018, 1–14. 
Bern, C., Kjos, S., Yabsley, M. J., & Montgomery, S. P. (2011). Trypanosoma cruzi and Chagas’  
Disease in the United States. Clin Microbiol Rev, 24(4), 655–681.  
Bivona, A. E., Sánchez Alberti, A., Matos, M. N., Cerny, N., Cardoso, A. C., Morales, C., …  
Malchiodi, E. L. (2018). Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a 
novel immunogen for Chagas disease vaccine.  
Brenière, S. F., Waleckx, E., & Barnabé, C. (2016). Over Six Thousand Trypanosoma cruzi  
Strains Classified into Discrete Typing Units (DTUs): Attempt at an Inventory. PLoS 
Neglected Tropical Diseases, 10(8), e0004792.  
Carrea, A., & Diambra, L. (2016). Systems Biology Approach to Model the Life Cycle of  
Trypanosoma cruzi. PLoS One, 11(1), e0146947.  
 REVIEW OF CHAGAS DISEASE 
 
32 
Carvalho, A. B., Goldenberg, R., & Campos de Carvalho, A. C. (2017). Cell therapies for  
Chagas disease. Cytotherapy, 19(11), 1339–1349.  
Chagas disease in Latin America: an epidemiological update based on 2010 estimates. (2015).  
Releve Epidemiologique Hebdomadaire, 90(6), 33–43. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/25671846 
Ciccarelli, A. B., Frank, F. M., Puente, V., Malchiodi, E. L., Batlle, A., & Lombardo, M. E.  
(2012). Antiparasitic Effect of Vitamin B12 on Trypanosoma cruzi. Antimicrobial Agents 
and Chemotherapy, 56(10), 5315–5320.  
Curtis-Robles, R., Wozniak, E. J., Auckland, L. D., Hamer, G. L., & Hamer, S. A. (2015).  
Combining Public Health Education and Disease Ecology Research: Using Citizen 
Science to Assess Chagas Disease Entomological Risk in Texas. PLOS Neglected 
Tropical Diseases, 9(12), e0004235.  
Edimar Alcides, B., Reinaldo Bulgarelli, B., Mauricio Ibrahim, S., Edecio Cunha, N., & Victor  
Sarli, I. (2017). Chronic Chagas Heart Disease Management. Journal of the American 
College of Cardiology, 70(12), 1510–1524.  
Isselbacher, E. M., Kligerman, S. J., Lam, K. M., & Hurtado, R. M. (2010). Case 2-2010. New  
England Journal of Medicine, 362(3), 254–262.  
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S.  
P. (2003). CD4+ T cells are required for secondary expansion and memory in CD8+ T 
lymphocytes. Nature, 421(6925), 852–856.  
Longo, D. L., & Bern, C. (2015). Chagas’ Disease. The New England Journal of Medicine,  
373(5), 456–466.  
Menezes, C., Costa, G. C., Gollob, K. J., & Dutra, W. O. (2011). Clinical aspects of Chagas  
 REVIEW OF CHAGAS DISEASE 
 
33 
disease and implications for novel therapies. Drug Development Research, 72(6), 471–
479.  
Meymandi, S. K., Forsyth, C. J., Soverow, J., Hernandez, S., Sanchez, D., Montgomery, S. P., &  
Traina, M. (2017). Prevalence of Chagas Disease in the Latin American-born Population 
of Los Angeles. Clinical Infectious Diseases : An Official Publication of the Infectious 
Diseases Society of America, 64(9), 1182–1188.  
Moncayo, Á. (2010). Carlos Chagas: Biographical sketch. Acta Tropica, 115(1–2), 1–4.  
Nunes, M. C., Dones, W., Morillo, C. A., Encina, J. J., Ribeiro, A. L., & Council on Chagas  
Disease of the Interamerican Society of, C. (2013). Chagas disease: an overview of 
clinical and epidemiological aspects. J Am Coll Cardiol, 62(9), 767–776.  
Pérez-Ayala, A., Pérez-Molina, J. A., Norman, F., Navarro, M., Monge-Maillo, B., Díaz- 
Menéndez, M., … López-Vélez, R. (2011). Chagas disease in Latin American migrants: a 
Spanish challenge. Clinical Microbiology and Infection, 17(7), 1108–1113.  
Pérez-Molina, J. A., & Molina, I. (2018). Chagas disease. The Lancet, 391(10115), 82–94.  
Providello, M. V., Carneiro, Z. A., Portapilla, G. B., do Vale, G. T., Camargo, R. S., Tirapelli, C.  
R., & de Albuquerque, S. (2018). Benefits of Ascorbic Acid in Association with Low-
Dose Benznidazole in Treatment of Chagas Disease. Antimicrobial Agents and 
Chemotherapy, 62(9), e00514-18.  
Puente, V., Demaria, A., Frank, F. M., Batlle, A., & Lombardo, M. E. (2018). Anti-parasitic  
effect of vitamin C alone and in combination with benznidazole against Trypanosoma 
cruzi. PLOS Neglected Tropical Diseases, 12(9), e0006764.  
Rassi, A., Rassi, A., & Marin-Neto, J. A. (2010). Chagas disease. The Lancet, 375(9723), 1388– 
1402.  
 REVIEW OF CHAGAS DISEASE 
 
34 
Ribeiro, F. A. P., Pontes, C., Gazzinelli, R. T., Romero, O.-B., Lazzarin, M. C., dos Santos, J. F.,  
… Ribeiro, D. A. (2019). Therapeutic effects of vaccine derived from amastigote surface 
protein-2 (ASP-2) against Chagas disease in mouse liver. Cytokine, 113, 285–290.  
Telleria, J., & Tibayrenc, M. (2017). American Trypanosomiasis Chagas Disease : One Hundred  
Years of Research. Elsevier Science.  
Silva, J. S., Machado, F. S., & Martins, G. A. (2003). The role of nitric oxide in the pathogenesis  
of Chagas disease. Frontiers in Bioscience : A Journal and Virtual Library, 8, s314-25.  
Teixeira, A. R., Hecht, M. M., Guimaro, M. C., Sousa, A. O., & Nitz, N. (2011). Pathogenesis of  
chagas’ disease: parasite persistence and autoimmunity. Clin Microbiol Rev, 24(3), 592–
630.  
Vilar-Pereira, G., Pereira, I. R., Ruivo, L. A. de S., Moreira, O. C., Silva, A. A. da, Britto, C., &  
Lannes-Vieira, J. (2016). Combination Chemotherapy with Suboptimal Doses of 
Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas’ 
Heart Disease. Antimicrobial Agents and Chemotherapy, 60(7), 4297–4309.  
 
  
 REVIEW OF CHAGAS DISEASE 
 
35 
Appendix A 
 
Prevalence 
rate of T. 
cruzi 
infection 
per 100 
inhabitants  
Number 
of people 
with a T. 
cruzi  
infection 
Number of 
new annual 
cases due to 
vector 
transmission 
Number of 
people with 
Chagasic 
cardiopathy 
Prevalence 
rate of T. 
cruzi 
infection 
per 100 US 
immigrants 
Prevalence 
rate of T. 
cruzi 
infection 
per 100 
European 
immigrants 
Argentina 3.6 1,500,000* 1100 380,000* -- 2.2 
Belize 0.33 1,000 10 200 -- -- 
Bolivia 6.1* 610,000 8100 120,000 25.79* 18.1* 
Brazil 0.03 1,200,000 46 230,000 -- 0.6 
Ecuador 1.4 200,000 2,000 40,000 -- 0.4 
El Salvador 1.3 90,000 970 18,000 3.66 5.6 
Guatemala 1.2 170,00 1,300 21,000 2.88 -- 
Honduras  73,000 930 15,000 2.94 3.7 
Mexico 0.8 880,000 6,100* 70,000 -- 1.5 
Paraguay 2.1 180,000 300 33,000 -- 5.5 
 
Table 1. Approximated epidemics and demographics of Chagas disease in 10 Latin American 
countries (“Chagas disease in Latin America”).  
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F
ig
u
re
 1
. 
T
h
e 
li
fe
 c
y
cl
e 
o
f 
T
. 
cr
u
zi
, 
sh
o
w
in
g
 v
ar
io
u
s 
st
ag
es
 a
n
d
 t
ra
n
sm
is
si
o
n
 p
o
in
ts
. 
